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Background: Diabetes (DM) and renal insufﬁciency (RI) have been reported as risk
factors for cardiovascular events. However, few studies have evaluated the effect of
DM and RI in acute coronary syndrome (ACS). The aim of this study was to assess the
synergistic effect of DM and RI on cardiovascular outcomes after successful percu-
taneous coronary intervention (PCI) with drug-eluting stent (DES).
Methods: A total of 2158 consecutive patients with ACS who underwent PCI with
DES were divided into 4 groups based on the presence or absence of DM and RI
(glomerular ﬁltration rate <60ml/min/1.73m2). We analyzed the incidence of major
adverse cardiac events (MACE), including cardiovascular death, nonfatal myocardial
infarction and target lesion revascularization after 2-year clinical follow-up.
Results: Primary endpoints occurred in 218 (10.1%) patients. There were signiﬁcant
differences in MACE among 4 groups (282 patients with DM+RI+, 17.7%, 422
patients with DM-RI+, 12.1%; 296 patients with DM+RI-, 8.4%; 1158 patients with
DM-RI-, 7.9%; p<0.001). In Cox analysis, after adjustment for confounding factors,
presence of both DM and RI was independent predictor of MACE.Hazard ratio (95% conﬁdence interval)
No adjustment P value Adjustment P value
DM-RI- 1 1
DM+RI- 1.068 (0.687-1.662) 0.769 1.042 (0.658-1.652) 0.860
DM-RI+ 1.558 (1.106-2.193) 0.011 1.207 (0.806-1.808) 0.362
DM+RI+ 2.353 (1.668-3.321) <0.001 1.932 (1.291-2.892) 0.001Conclusions: Concurrence of DM and RI is an independent predictor of adverse
cardiovascular outcomes in ACS patients undergoing PCI with DES.
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Background: Acute myocardial infarction (MI) is a major cause of death among
patients with diabetes mellitus (DM), even after primary percutaneous coronaryB72 JACC Vol 62/18/Suppl B j October 2intervention (PCI). We sought to evaluate the clinical, angiographic and cardiac MRI
results in patients with and without DM undergoing primary PCI for ST-elevation
myocardial infarction (STEMI).
Methods: In the INFUSE-AMI trial, patients with anterior STEMI due to an occluded
left anterior descending artery (LAD) undergoing primary PCI with bivalirudin anti-
coagulation were randomized to intralesional delivery of intracoronary abciximab vs.
control and to thrombus aspiration or not. Angiographic baseline and post procedure
analysis, cardiac MRI at 30 days and clinical follow-up at 30 days and at 1 year were
performed and compared between DM (n¼51) and non-DM (n¼400) patients.
Results: Patients with DM had more comorbidities and more extensive LAD disease
than non-DM. Primary PCI was equally effective in DM and non-DM in restoring
TIMI-3 ﬂow, ST-segment resolution at 60 minutes and 30-day infarct size (14.3%
[7.1, 24.5] vs. 17.3% [8.1, 23.6], p¼0.55). Stent thrombosis (ST) within 30 days after
primary PCI was higher in DM than non-DM patients (4.3% vs. 0.8%, p¼0.03), and at
1 year DM patients had more major cardiovascular and cerebrovascular events
(MACCE) (16.5% vs. 8.0%, p¼0.04; Figure).Conclusions: Patients with DM presenting with STEMI have a higher baseline risk
proﬁle than those without DM. Although reperfusion success and infarct size were
similar, DM patients experienced more death, reinfarction, stent thrombosis and
revascularization than non-diabetics.
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Background: Percutaneous coronary intervention (PCI) is the recommended reper-
fusion strategy for patients presenting with ST-elevation myocardial infarction
(STEMI). Per the guidelines stent type (bare metal (BMS) vs drug-eluting (DES))
choice is mainly left at the operator’s discretion. Our hypothesis is that stent choice is
inﬂuenced by factors such as insurance, ethnicity, race, and gender.
Methods: Prospectively collected data from 1/1/11 till 12/31/12 at 2 tertiary care
centers in the New York area was obtained. Univariate, bivariate and multivariate
analyses for gender, ethnicity, race, and insurance type were performed. The
primary endpoint was death (index admission or 30-day). The secondary one was
adverse outcome (death, dissection, perforation, MI, CVA, bleeding, transfusion, or
CABG).
Results: Among the 1,442 patients presenting with STEMI who underwent PCI
(1,101 DES, 342 BMS) BMS patients were older, more often of white race and female
gender, with higher prevalence of previous surgery (valve or bypass), bigger vessel
diameter, and smaller stent length than DES patients. DES use was associated with
lower mortality (1% vs 7%, p<0.001) and adverse events (7% vs 23%, p<0.001).
These results were conﬁrmed in multivariate and stratiﬁed analyses.7–November 1, 2013 j TCT Abstracts/POSTER/STEMI/NSTEMI/ACS
Table 1. Characteristics of the study population overall and by stent type*
Overall (n=1,442) BMS (n=341) DES (n=1,101) p
Age (y) 64  13 65.6  14.9 63.1  12.0 0.002
Male 1,053 (73%) 217 (64%) 836 (76%) <0.001
Race 0.013
White 869 (60%) 214 (63%) 655 (59%)
Black 181 (13%) 54 (16%) 127 (12%)
Asian 241 (17%) 49 (14%) 192 (17%)
Other 151 (10%) 24 (7%) 127 (12%)
Hispanic 112 (8%) 31 (9%) 81 (7%) 0.273
Insurance 0.237
None/Military/State 103 (7%) 31 (9%) 72 (7%)
Medicare/Medicaid 257 (18%) 56 (16%) 201 (18%)
Private 1,082 (75%) 254 (74%) 828 (75%)
Smoking 362 (25%) 106 (31%) 256 (23%) 0.004
HTN 1,023 (71%) 248 (73%) 775 (71%) 0.432
Dyslipidemia 945 (66%) 208 (61%) 737 (67%) 0.037
Family Hx of CAD 189 (13%) 55 (16%) 134 (12%) 0.066
Prior MI 208 (14%) 56 (11%) 172 (16%) 0.019
Prior CHF 66 (5%) 28 (8%) 38 (3%) <0.001
Prior valve surgery 21 (1%) 12 (4%) 9 (1%) <0.001
Prior PCI 320 (22%) 68 (20%) 252 (23%) 0.237
Prior CABG 71 (5%) 30 (9%) 41 (4%) <0.001
Dialysis 15 (1%) 3 (1%) 12 (1%) 0.740
Prior CVD 78 (5%) 26 (8%) 52 (5%) 0.039
Prior PAD 60 (4%) 37 (11%) 23 (2%) <0.001
Chronic lung disease 49 (3%) 28 (8%) 21 (2%) <0.001
Diabetes 433 (30%) 84 (25%) 349 (32%) 0.013
Anti-anginal medication 584 (41%) 147 (43%) 437 (40%) 0.261
Beta blockers 418 (72%) 104 (71%) 314 (72%) 0.797
Calcium channel blockers 265 (45%) 83 (56%) 182 (42%) 0.002
Long-acting nitrates 104 (18%) 20 (14%) 84 (19%) 0.124
Ranolazine 5 (1%) 0 (0%) 5 (1%) 0.338
Femoral access 1,317 (91%) 317 (93%) 1,000 (91%) 0.221
In-Stent Restenosisy 54 (56%) 10 (40%) 45 (62%) 0.067
Stent Thrombosisy 69 (70%) 23 (92%) 46 (63%) 0.006
Vessels involved
Left main 25 (2%) 6 (2%) 19 (2%) 0.967
LAD 805 (56%) 161 (47%) 644 (58%) <0.001
LCx 517 (36%) 116 (34%) 401 (36%) 0.419
RCA 856 (59%) 221 (65%) 635 (58%) 0.020
Ramus 33 (2%) 5 (1%) 28 (3%) 0.304
LAD graft 13 (1%) 6 (2%) 7 (1%) 0.055
LCx graft 43 (3%) 24 (7%) 19 (2%) <0.001
RCA graft 25 (2%) 12 (4%) 13 (1%) 0.007
Ramus graft 0 (0%) 0 (0%) 0 (0%) 1.000
Vessel diameter (mm) 2.9  0.5 3.1  0.6 2.9  0.4 <0.001
Lesion length (mm) 27.0  15.4 28.1  18.0 26.6  14.5 0.120
Stent length (mm) 19.8  6.3 18.9  5.6 20.0  6.4 0.004
Adverse outcome 157 (11%) 79 (23%) 78 (7%) <0.001
Dissection 21 (2%) 9 (3%) 12 (1%) 0.037
Perforation 8 (1%) 1 (1%) 7 (1%) 0.689
Myocardial infarction 8 (1%) 0 (0%) 8 (1%) 0.210
CVA 2 (1%) 1 (1%) 1 (1%) 0.418
Transfusion 105 (7%) 60 (18%) 45 (4%) <0.001
Bleeding 43 (3%) 33 (10%) 10 (1%) <0.001
CABG 1 (1%) 1 (1%) 0 (0%) 0.236
Death 30 (2%) 25 (7%) 5 (1%) <0.001
HTN ¼ Hypertension.
Discrete variables are provided as frequency (%).
Continuous variables are provided as mean  standard deviation.
*n ¼ 1,442.
yn ¼ 98.
Table 2. End points by stent type across divides of interest*
BMS (n = 341) DES (n = 1,101) p
Female
Death 18 (15%) 2 (1%) <0.001
Adverse outcome 40 (32%) 13 (5%) <0.001
Male
Death 7 (3%) 3 (1%) <0.001
Adverse outcome 39 (18%) 65 (8%) <0.001
Non Hispanic
Death 19 (6%) 5 (1%) <0.001
Adverse outcome 70 (23%) 64 (6%) <0.001
Hispanic
Death 6 (19%) 0 (0%) <0.001
Adverse outcome 7 (23%) 2 (2%) <0.001
White
Death 20 (9%) 5 (1%) <0.001
Adverse outcome 52 (24%) 48 (7%) <0.001
Black
Death 0 (0%) 0 (0%) 1.000
Adverse outcome 20 (37%) 5 (4%) <0.001
Asian
Death 5 (10%) 0 (0%) <0.001
Adverse outcome 6 (12%) 12 (6%) 0.154
Other
Death 0 (0%) 0 (0%) 1.000
Adverse outcome 1 (4%) 13 (10%) 0.347
None/Military/State
Death 1 (3%) 2 (3%) 0.901
Adverse outcome 1 (3%) 2 (3%) 0.901
Private
Death 13 (5%) 3 (1%) <0.001
Adverse outcome 64 (25%) 66 (8%) <0.001
Medicare/Medicaid
Death 11 (20%) 0 (0%) <0.001
Adverse outcome 14 (25%) 10 (5%) <0.001
*End points reported as frequency since unadjusted and adjusted odds ratios frequently
showed perfect prediction of outcome. When numerical odds ratios were available the results
were similar to the reported frequencies.
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patients undergoing PCI highlighting a bias in our practice. Except for patients with
the most limited insurance status all subjects showed better outcomes with DES which
should be considered as the preferred option in STEMI patients.
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Background: Right ventricular (RV) infarction (RVI) is associated with an unfa-
vorable prognosis, however there is a paucity of data regarding the factors which are
the real causes of the RVI. This study was designed to determine the impact of
primary percutaneous coronary intervention effect on the presence of RVI evaluated
by late enhancement cardiovascular magnetic resonance.
Methods: We prospectively assessed the association between the ﬂow in major
(1 mm) RV branches before and after primary PCI of Right Coronary Artery (RCA)
in 114 patients with the ﬁrst acute inferior myocardial infarction. In 3-5 days after
coronary reperfusion with PCI, cardiovascular magnetic resonance was performed for
assessing the presence of late enhancement in the RV wall.
Results: The only two angiographical factors that caused the presence of RV
infarction were TIMI<2 ﬂow in at least one RV branch (odds ratio 143; 95 percent
conﬁdence interval 18.1 to 1130.0; p <0.001), and distal embolization of posterioracts/POSTER/STEMI/NSTEMI/ACS B73
